Accelerate Your Psoriasis Drug Discovery with MLM’s IL-23-Induced and IMQ-Induced Preclinical Disease Models

As winter sweeps across the United States with record-breaking cold temperatures, researchers studying psoriasis and related skin diseases are uniquely positioned to address the heightened challenges these conditions present. The dry, frigid air exacerbates symptoms for individuals with psoriasis amplifying the critical need for innovative solutions in dermatological care.

At MLM Medical Labs, we specialize in advancing preclinical research to address complex skin conditions like psoriasis. Two cornerstone preclinical models in this area—the IL-23-induced psoriasis model and the IMQ-induced psoriasis model—offer researchers unparalleled opportunities to deepen their understanding of disease mechanisms and evaluate therapeutic interventions.

Let’s dive into why these models are essential tools in dermatological research and how they can drive innovation.

IL-23-Induced Psoriasis Model

Psoriasis researchers have long recognized the critical role of IL-23 in driving disease pathology. The IL-23-induced psoriasis model enables a precise examination of the immune pathways that contribute to disease progression.

Why This Model?

• Pathway Specificity: Replicates the IL-23/IL-17 axis, offering insights into a primary driver of psoriasis inflammation.
• Therapeutic Validation: Serves as an ideal platform for testing biologics and other agents targeting IL-23.
• Chronic Disease Study: Facilitates long-term studies on inflammation and therapeutic durability.

This model empowers researchers to explore targeted therapies that could redefine psoriasis management by addressing the disease at its molecular core.

Download the IL-23 Psoriasis Model Datasheet
Explore MLM’s Full Range of Preclinical Solutions

IMQ-Induced Psoriasis Models

For researchers seeking rapid and reproducible results, the IMQ-induced psoriasis models are a reliable choice. This model leverages imiquimod’s ability to activate toll-like receptors 7 and 8, inducing psoriatic-like lesions in mice or rats.

Key Advantages:

• Efficiency: Delivers observable results quickly, streamlining study timelines.
• Versatility: Suitable for investigating topical and systemic therapies.
• Immune Profiling: Offers comprehensive insights into both innate and adaptive immune responses.

The IMQ model is a vital resource for understanding the immunological underpinnings of psoriasis and assessing potential interventions.

Download the IMQ Psoriasis Model Datasheets:

• • • IMQ Psoriasis Mouse
    • IMQ Psoriasis Rat

Explore MLM’s Full Range of Preclinical Solutions

Addressing Winter’s Impact Through Research

Winter’s environmental challenges often serve as a catalyst for disease exacerbation, reminding researchers of the urgency to develop effective treatments. Preclinical models like IL-23 and IMQ offer controlled settings to explore these seasonal impacts, enabling scientists to refine therapeutic strategies that can provide relief year-round.

Why Partner with MLM Medical Labs?

At MLM Medical Labs, we understand the complexities you face as experts in dermatological research. Our advanced capabilities with IL-23 and IMQ-induced psoriasis models, combined with state-of-the-art facilities, position us as an ideal partner for your investigative needs. Whether you aim to unravel disease mechanisms or validate novel therapies, we’re here to support your journey toward transformative breakthroughs.

Ready to innovate? 

Contact us to explore how our psoriasis models can support your research breakthroughs. Together, let’s create a brighter future for dermatological care.

Email Us: info@mlm-labs.com or directly at katie.dineen@mlm-labs.com
Contact Us: Visit MLM’s Contact Page